Priority Assets


Our Priority Assets are largely maturing clinical development companies, nearing significant value inflection points.

Viamet represents a financial interest in a Phase 3 compound for the treatment of recurrent vulvovaginal candidiasis (RVVC), an unmet need in women's health, and onychomycosis (OM), fungal nail infection.

Viamet’s most advanced molecule, VT-1161, was acquired by NovaQuest Capital Management in January 2018. The acquisition of this molecule followed the successful Phase 2b clinical trials for the treatment of RVVC and OM announced in 2017.

Mycovia is responsible for the further development of VT-1161 and successful progression of this molecule through clinical trials and commercialisation will provide a substantial cash flow to Malin.

Viamet Pipeline

Candidate

Indication

IND-enabling

Phase 1

Phase 2

Phase 3

VT-1161

Recurrent vulvovaginal candidiasis

VT-1161

Onychomycosis

VT-1598

Cryptococcal meningitis

Candidate: VT-1161

Indication: Recurrent vulvovaginal candidiasis

IND-enabling

Phase 1

Phase 2

Phase 3

VT-1161

Indication: Onychomycosis

IND-enabling

Phase 1

Phase 2

Phase 3

Candidate: VT-1129

Indication: Cryptococcal meningitis

IND-enabling

Phase 1

Phase 2

Phase 3